Literature DB >> 24478433

Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin.

Jie Lu1, Hem C Jha, Subhash C Verma, Zhiguo Sun, Shuvomoy Banerjee, Richard Dzeng, Erle S Robertson.   

Abstract

UNLABELLED: Kaposi's sarcoma-associated herpesvirus (KSHV) is a human gammaherpesvirus casually linked to Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma (PEL). Previously, we showed that LANA encoded by KSHV upregulates expression of survivin, a member of the inhibitor of apoptosis (IAP) family. This leads to an increase in the rate of cell proliferation of KSHV-infected B cells. LANA is required for tethering of the KSHV episome to the host chromosomes and efficiently segregates the viral genomes into dividing tumor cells. Here we show that LANA interacts with Aurora kinase B (AK-B) and induces phosphorylation of survivin at residue T34. Phosphorylation of survivin specifically on residue T34 enhances the activity of p300 and inhibits the activity of histone deacetylase 1 (HDAC-1), which then leads to an increase in acetylation of histone H3 on the viral genome. Phosphorylation of survivin specifically on residue T34 upregulates the activities of histone acetyltransferases and deacetylases, which then leads to an increase in viral copy number in KSHV-infected B cells. This results in a boost of KSHV replication in latently infected B-lymphoma cells. The studies showed that LANA can also function to regulate viral replication prior to mitosis of the latently infected cells, suggesting that LANA possesses a novel role in regulating KSHV replication in infected B cells. IMPORTANCE: This work represents a report of KSHV latent protein LANA and its interactions with AK-B leading to induction of phosphorylation of the oncoprotein survivin at residue T34. Phosphorylation of survivin specifically on residue T34 upregulates the activities of histone acetyltransferases and deacetylases. This leads to an increase in viral copy number in KSHV-infected B cells. These studies support a role for LANA in regulating KSHV replication through posttranslation modification in KSHV-infected B cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24478433      PMCID: PMC3993767          DOI: 10.1128/JVI.03855-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  93 in total

1.  Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells.

Authors:  Jun Chen; Sha Jin; Stephen K Tahir; Haichao Zhang; Xuesong Liu; Aparna V Sarthy; Thomas P McGonigal; Zhihong Liu; Saul H Rosenberg; Shi-Chung Ng
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

2.  Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.

Authors:  Jie Lu; Masanao Murakami; Subhash C Verma; Qiliang Cai; Sabyasachi Haldar; Rajeev Kaul; Mariusz A Wasik; Jaap Middeldorp; Erle S Robertson
Journal:  Virology       Date:  2010-11-19       Impact factor: 3.616

3.  Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

Authors:  Marzia Pennati; Allyson J Campbell; Maria Curto; Mara Binda; Yuzhu Cheng; Lan-Zeng Wang; Nicola Curtin; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Andrew Henderson; Nadia Zaffaroni; David R Newell
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

4.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

5.  The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters.

Authors:  A K Groves; M A Cotter; C Subramanian; E S Robertson
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2.

Authors:  Stephan Ryser; Eva Dizin; Charles Edward Jefford; Bénédicte Delaval; Sarantis Gagos; Agni Christodoulidou; Karl-Heinz Krause; Daniel Birnbaum; Irmgard Irminger-Finger
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells.

Authors:  S Santag; W Jäger; C B Karsten; S Kati; M Pietrek; D Steinemann; G Sarek; P M Ojala; T F Schulz
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

8.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1.

Authors:  Subhash C Verma; Sumit Borah; Erle S Robertson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  The RBP-Jκ binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation.

Authors:  Jie Lu; Subhash C Verma; Qiliang Cai; Abhik Saha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

10.  Histone acetylation mediates epigenetic regulation of transcriptional reprogramming in insects during metamorphosis, wounding and infection.

Authors:  Krishnendu Mukherjee; Rainer Fischer; Andreas Vilcinskas
Journal:  Front Zool       Date:  2012-10-04       Impact factor: 3.172

View more
  13 in total

1.  Major Histocompatibility Complex Class II HLA-DRα Is Downregulated by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Lytic Transactivator RTA and MARCH8.

Authors:  Zhiguo Sun; Hem Chandra Jha; Yong-Gang Pei; Erle S Robertson
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

Review 2.  Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.

Authors:  Denis Avey; Brittany Brewers; Fanxiu Zhu
Journal:  Virol Sin       Date:  2015-04-23       Impact factor: 4.327

3.  Kaposi's sarcoma-associated herpesvirus-encoded LANA can induce chromosomal instability through targeted degradation of the mitotic checkpoint kinase Bub1.

Authors:  Zhiguo Sun; Bingyi Xiao; Hem Chandra Jha; Jie Lu; Shuvomoy Banerjee; Erle S Robertson
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 4.  How do viruses trick B cells into becoming lymphomas?

Authors:  Ethel Cesarman
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

5.  Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cells.

Authors:  Richard K Dzeng; Hem Chandra Jha; Jie Lu; Abhik Saha; Sagarika Banerjee; Erle S Robertson
Journal:  Mol Oncol       Date:  2014-09-26       Impact factor: 6.603

Review 6.  KSHV LANA--the master regulator of KSHV latency.

Authors:  Timsy Uppal; Sagarika Banerjee; Zhiguo Sun; Subhash C Verma; Erle S Robertson
Journal:  Viruses       Date:  2014-12-11       Impact factor: 5.048

Review 7.  SUMO and KSHV Replication.

Authors:  Pei-Ching Chang; Hsing-Jien Kung
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 8.  The Modulation of Apoptotic Pathways by Gammaherpesviruses.

Authors:  Shuvomoy Banerjee; Timsy Uppal; Roxanne Strahan; Prerna Dabral; Subhash C Verma
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

Review 9.  Cell Cycle Regulatory Functions of the KSHV Oncoprotein LANA.

Authors:  Fang Wei; Jin Gan; Chong Wang; Caixia Zhu; Qiliang Cai
Journal:  Front Microbiol       Date:  2016-03-30       Impact factor: 5.640

10.  KSHV-Mediated Regulation of Par3 and SNAIL Contributes to B-Cell Proliferation.

Authors:  Hem C Jha; Zhiguo Sun; Santosh K Upadhyay; Darine W El-Naccache; Rajnish K Singh; Sushil K Sahu; Erle S Robertson
Journal:  PLoS Pathog       Date:  2016-07-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.